The trial met its primary endpoint with a hazard ratio of 0.75, indicating a significant reduction in disease progression ...

Incyte said on Monday its experimental combo therapy helped patients live longer without their disease worsening in a late-stage study of a type of blood cancer, sending its shares up about 3% in ...

June 3, 2012 (Chicago, Illinois) — New long-term results from a German trial of patients with indolent and slow-growing lymphoma confirm that a simpler 2-drug combination can be used in these patients ...

Odronextamab combined with CHOP chemotherapy shows high efficacy in untreated DLBCL, with a 100% response rate at the 160 mg dose. The safety profile of odronextamab-CHOP is manageable, with common ...

Incyte said on Monday its experimental combo therapy helped patients with a type of blood cancer live longer without their ...

From Philly and the Pa. suburbs to South Jersey and Delaware, what would you like WHYY News to cover? Let us know! At 8 years old, Raine Talley spent a lot of time in and out of children’s hospitals ...